Dear Ms. Raposo:

Please refer to your supplemental new drug applications dated and received April 4, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lexapro (escitalopram oxalate) tablets (NDA 21-323), and Lexapro (escitalopram oxalate) solution (NDA 21-365).

These “Changes Being Effected” supplemental new drug applications provide for class labeling changes to the Events Reported Subsequent to the Marketing of Escitalopram Section of the Labeling:

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission “SPL for approved supplement NDA 21- NDA 21-323/S-029 and NDA 21-365/S-019.”

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Renmeet Grewal, Pharm.D., Senior Regulatory Project Manager, at (301) 796-1080.

Sincerely,

(See appended electronic signature page)

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Thomas Laughren
10/11/2008 11:26:07 AM